YvonneA.EfeberaMDMPH

Hematology • Columbus, OH

Associate Professor, Dept of Internal Medicine, Division of Hematology, The Ohio State University.

Join to view full profile

Dr. Efebera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Efebera's full profile

Already have an account?

Office
460 W 10th Ave
5th Floor
Columbus, OH 43210
Phone+1 614-293-3196

Fax+1 614-293-4812
Is this information wrong?

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Cleveland Clinic FoundationResidency, Internal Medicine, 1998 - 2001
Pennsylvania State University College of MedicineClass of 1998

Certifications & Licensure

OH State Medical License 2000 - 2025
TX State Medical License 2008 - 2022
MA State Medical License 2004 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation Start of enrollment: 2011 Dec 10
Completed
Phase 2
Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease Start of enrollment: 2012 Feb 20
Recruiting
Brentuximab Vedotin for Steroid Refractory GvHD Start of enrollment: 2012 Jul 01
Completed
Phase 1
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Mar 03
Terminated
Phase 1
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Mar 21
Terminated
Phase 2
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma Start of enrollment: 2020 Dec 22
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya M Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Bad...> ;British Journal of Haematology. 2024 Mar 19
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.
Fu, P., Li, G., Malek, E., Kort, J., Metheny, L., Hari, P., Efebera, Y., Callander, N., Qazilbash, M., Giralt, S., Krishnan, A., Stadtmauer, E., Lazarus, H.> ;Transplantation and Cellular Therapy. 2024 Jan 19
Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States.
Tondre Buck, Monique A Hartley-Brown, Yvonne A Efebera, Carter P Milner, Jeffrey A Zonder, Paul G Richardson, Taylor Salinardi, Megan S Rice> ;Haematologica. 2023 Nov 30
Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
Amro M Stino, Naresh Bumma, Rachel Smith, Long Davalos, Jeff Allen, Jing Christine Ye, Matthew Pianko, Erica Campagnaro, Cassandra Fierro, Abdelrahman Awad, Ben Murdoc...> ;European Journal of Neurology. 2024 Mar 1
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.
Alessandro Canella, Hector Cordero Nieves, Douglas W Sborov, Luciano Cascione, Hanna S Radomska, Emily Smith, Andrew Stiff, Jessica Consiglio, Enrico Caserta, Lara Riz...> ;Oncotarget. 2023 Sep 25
Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial.
Ehsan Malek, Jeries Kort, Leland Metheny, Pingfu Fu, Parameswaran Hari, Gen Li, Yvonne Efebera, Natalie Callander, Muzaffar Qazilbash, Sergio Giralt, Amrita Krishnan, ...> ;Research Square. 2023 Sep 21
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Enrique M Ocio, Yvonne A Efebera, Roman Hájek, Jan Straub, Vladimir Maisnar, Jean-Richard Eveillard, Lionel Karlin, María-Victoria Mateos, Albert Oriol, Vincent Ribrag...> ;Haematologica. 2024 Mar 1
11 citations
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P Hammond, Alexander M Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krin...> ;Blood Cancer Journal. 2023 Aug 1
1 citations
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multip...
David J Chung, Nina Shah, Juan Wu, Brent Logan, Lina Bisharat, Natalie Callander, Giulia Cheloni, Kenneth Anderson, Thinle Chodon, Binod Dhakal, Steve Devine, Poorvi S...> ;Clinical Cancer Research. 2023 Dec 1
42 citations
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Javier Bolaños-Meade, Mehdi Hamadani, Juan Wu, Monzr M Al Malki, Michael J Martens, Lyndsey Runaas, Hany Elmariah, Andrew R Rezvani, Mahasweta Gooptu, Karilyn T Larkin...> ;The New England Journal of Medicine. 2023 Jun 22
Survival outcomes following autologous stem cell transplant with melphalan 140mg/mversus 200mg/mpreparative regimens in patients with multiple myeloma.
Nidhi Sharma, Evan Benson, Qiuhong Zhao, Jordan Nunnelee, Francesca Cottini, Patrick Elder, Ashley Rosko, Naresh Bumma, Abdullah Khan, Elvira Umyarova, Srinivas Devara...> ;Leukemia & Lymphoma. 2023 May 18
Editorial: Autologous and Allogeneic Stem Cell Transplant in Cancer Therapy.
Nidhi Sharma, Yvonne A Efebera> ;Cancers. 2023 Feb 21
A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the G...
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Badro...> ;Future Oncology. 2022 Dec 1
Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple ...
Abdullah M Khan, Filiz Yucebay, Qiuhong Zhao, Elvira Umyarova, Francesca Cottini, Naresh Bumma, Ashley Rosko, Don Benson, Nidhi Sharma, Yvonne Efebera, Srinivas Devara...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Feb 1
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.
Muhammad Salman Faisal, Walter Hanel, Timothy Voorhees, Rui Li, Ying Huang, Abdullah Khan, David Bond, Yazeed Sawalha, John Reneau, Lapo Alinari, Robert Baiocchi, Beth...> ;Cancer Medicine. 2023 Apr 1
The first relapse in multiple myeloma: how to pick the next best thing.
Srinivas Devarakonda, Nidhi Sharma, Yvonne Efebera> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
1 citations
Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience.
Justin Jiang, Audrey M Sigmund, Qiuhong Zhao, Patrick Elder, Don M Benson, Sumithira Vasu, Samantha Jaglowski, Alice Mims, Hannah Choe, Karilyn Larkin, Jonathan E Bram...> ;Cancers. 2022 Nov 14
4 citations
Early versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma.
Jordan Nunnelee, Francesca Cottini, Qiuhong Zhao, Muhammad Salman Faisal, Patrick Elder, Ashley Rosko, Naresh Bumma, Abdullah Khan, Elvira Umyarova, Srinivas Devarakon...> ;Journal of Clinical Medicine. 2022 Sep 29
8 citations
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Douglas W Sborov, Muhamed Baljevic, Brandi Reeves, Jacob Laubach, Yvonne A Efebera, Cesar Rodriguez, Luciano J Costa, Ajai Chari, Rebecca Silbermann, Sarah A Holstein,...> ;British Journal of Haematology. 2022 Nov 1
3 citations
Melphalan flufenamide for relapsed/refractory multiple myeloma.
Omar Nadeem, Maria-Victoria Mateos, Yvonne A Efebera, Agne Paner, Alessandra Larocca, Paula Rodríguez-Otero, Xavier Leleu, Paul G Richardson> ;Drugs of Today. 2022 Aug 1
2 citations
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the ...
Qaiser Bashir, Taiga Nishihori, Marcelo C Pasquini, Michael J Martens, Juan Wu, Melissa Alsina, Claudio Anasetti, Claudio Brunstein, Peter Dawson, Yvonne Efebera, Cris...> ;Transplantation and Cellular Therapy. 2023 Jun 1
11 citations
Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.
Anita D'Souza, Ruta Brazauskas, Edward A Stadtmauer, Marcelo C Pasquini, Parameswaran Hari, Asad Bashey, Natalie Callander, Steven Devine, Yvonne Efebera, Siddhartha G...> ;American Journal of Hematology. 2023 Jan 1
6 citations
Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience.
Jordan Nunnelee, Francesca Cottini, Qiuhong Zhao, Muhammad Salman Faisal, Patrick Elder, Ashley Rosko, Naresh Bumma, Abdullah Khan, Srinivas Devarakonda, Don M Benson,...> ;Cancers. 2022 May 3
4 citations
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.
Ajay K Nooka, Jonathan L Kaufman, Cesar Rodriguez, Andrzej Jakubowiak, Yvonne Efebera, Brandi Reeves, Tanya Wildes, Sarah A Holstein, Larry D Anderson Jr, Ashraf Badro...> ;Blood Cancer Journal. 2022 Apr 13
16 citations
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).
Angela Dispenzieri, Amrita Krishnan, Bonnie Arendt, Beth Blackwell, Paul K Wallace, Surendra Dasari, Dan T Vogl, Yvonne Efebera, Mingwei Fei, Nancy Geller, Sergio Gira...> ;Blood Cancer Journal. 2022 Feb 10
Join now to see all

Abstracts/Posters

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
AL Amyloidosis: The Effects of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
The Effect of Cytogenetic Abnormalities on Organ Involvement and Survival in Patients with AL Amyloidosis
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Improvement in Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Restoring Functional Deficits in Older Adults with Hematologic Malignancy
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory ...
Yvonne A. Efebera, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Lenalidomide and Vorinostat Maintenance after Autologous Transplant in Multiple Myeloma- Long Term Follow-up
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018